Table 1

Baseline demographics and disease characteristics (pooled placebo-controlled population and TCZ all-exposure population)

Pooled placebo-controlled populationTCZ all-exposure population
TCZ±MTX/DMARD
n=2644
Placebo+MTX/DMARDs
n=1454
Total
N=4009
DMARD-IR
n=2904
aTNF-IR
n=464
Female, n (%)2179 (82)1184 (81)3286 (82)2398 (83)373 (80)
Age, years52.2 (12.50)51.8 (12.83)52.0 (12.54)52.2 (12.39)52.6 (12.73)
Race, n (%)
 White1952 (74)1082 (74)2970 (74)2075 (71)421 (91)
 Asian202 (8)112 (8)304 (8)247 (9)11 (2)
American
 Indian/Alaska190 (7)95 (7)274 (7)218 (8)5 (1)
Native
 Black113 (4)60 (4)176 (4)124 (4)20 (4)
 Other187 (7)105 (7)285 (7)240 (8)7 (2)
 Duration of RA, years9.2 (8.41)8.7 (8.47)9.3 (8.51)9.4 (8.33)11.9 (9.10)
 DAS286.7 (0.98)6.7 (0.96)6.4 (1.28)6.4 (1.23)6.7 (1.12)
 Oral corticosteroid use, n (%)NANA2318 (58)1746 (60)(275 (59)
 ≥1 background DMARD, n (%)NANA3456 (86)2887 (99)464 (100)
 CRP, mg/dL2.6 (3.03)2.7 (3.64)2.4 (2.90)2.3 (2.73)3.1 (3.59)
 ESR, mm/h48.3 (26.75)49.1 (27.23)46.1 (26.83)46.1 (26.44)50.2 (28.24)
 Tender joint count30.4 (15.36)29.9 (15.13)28.0 (16.60)27.8 (16.41)31.0 (16.57)
 Swollen joint count18.8 (10.8)18.5 (10.61)17.3 (11.51)17.3 (11.32)18.7 (11.42)
  • All data are mean (SD) unless stated otherwise.

  • aTNF-IR, antitumour necrosis factor-inadequate responders; CRP, C reactive protein; DAS28, Disease Activity Score based on 28 joints; DMARD, disease-modifying antirheumatic drug; DMARD-IR, disease-modifying antirheumatic drug-inadequate responders; ESR, erythrocyte sedimentation rate; MTX, methotrexate; NA, not available; RA, rheumatoid arthritis; TCZ, tocilizumab.